Abstract The ultimate treatment for end-stage renal disease (ESRD) is orthotopic transplantation. However, the demand for kidney transplantation far exceeds the number of available donor organs. While more than 100,000 Americans need a kidney, only 17,000 people receive a kidney transplant each year (National Kidney Foundation's estimations). In recent years, several regenerative medicine/tissue engineering approaches have been exploited to alleviate the kidney shortage crisis. Although these approaches have yielded promising results in experimental animal models, the kidney is a complex organ and translation into the clinical realm has been challenging to date. In this review, we will discuss cell therapy-based approaches for kidney regeneration and whole-kidney tissue engineering strategies, including our innovative approach to regenerate a functional kidney using the lymph node as an in vivo bioreactor.
Introduction
The kidney is a multifunctional organ that performs several essential physiological functions, including excretion of metabolic wastes, osmoregulation, and secretion of hormones.
The regenerative capacity of the mammalian kidney is limited compared to that of lower vertebrates. The mammalian kidney cannot make new nephrons, and although some regeneration events take place following an acute kidney injury (AKI), they are exclusively confined to the tubular epithelium [1] . However, tubular regeneration is frequently incomplete and accompanied by fibrosis and long-term loss of function. In this situation, an episode of AKI leads to future chronic kidney disease (CKD).
The relatively young fields of regenerative medicine and tissue engineering have emerged as tools that can be tailored to restore tissue integrity and function. The fundamental building blocks of these disciplines are the stem cells, which are defined as undifferentiated cells with potentially unlimited proliferative and lineage potential [2] . While several stem cell-based strategies for kidney repair and regeneration have shown promise in small animal models, the clinical scalability of such approaches for human tissue is still unclear. In this review, we will discuss the numerous challenges that must be addressed before these techniques can be used clinically.
Cell-based therapy for kidney disease
While stem cell-based therapies offer tremendous potential for heart, liver, pancreas, or lung regeneration [3] , it is unclear whether patients with renal disease can benefit from a stem cell therapy. Evidence for resident stem cells in the mature mammalian kidney has been lacking [4] [5] [6] . Cellular phenotyping has largely relied upon expression of stemness markers such as CD133 and CD24 [7] . Both markers were shown to be co-expressed by a subset of parietal epithelial cells (PECs) in the Bowman's capsule [8] . Once isolated, CD24 + CD133 + PECs lacked lineage-specific markers; expressed transcription factors that are characteristic of multipotent stem cells; and exhibited self-renewal, high clonogenic efficiency, and multidifferentiation potential [8] . Importantly, when injected intravenously in mice with severe combined immunodeficiency (SCID) and acute renal failure, CD24 + CD133 + PECs regenerated tubular structures in different portions of the nephron and also reduced morphologic and functional kidney damage [8] . The label retaining cell (LRC) assay using the thymidine analog 5-bromo-2′-deoxyuridine (BrdU) was also used to identify slow-cycling renal cells, which are recognized as adult stem cells. Oliver et al. found that the renal adult papilla contains large numbers of BrdU-retaining cells which persist throughout the life of the animal but quickly enter the cell cycle and disappear from the papilla during recovery from a transient episode of ischemia, suggesting that these cells might participate in renal repair [9] . However, direct evidence that BrdU-retaining cells might be beneficial for kidney therapy cannot be provided, as BrdU detection procedure results in destruction of cell integrity, thus hampering further cell applications. Primitive renal cells have also been identified by their ability to exclude the DNA binding dye Hoechst 33342. This subpopulation, called side population (SP), was shown to improve renal function in experimental models of renal damage [10] . Nevertheless, given that the Hoechst dye efflux method likely identifies cells that do not reflect the entire stem cell cohort, a concomitant study of stem cell molecular markers is mandatory to complement and complete their characterization for clinical use.
Non-tissue-specific adult multipotent stem cells harvested from either bone marrow (BM) or peripheral blood, or less differentiated stem cells retrieved from extra-embryonic and fetal annexes (placenta, amniotic and chorionic membranes, umbilical cord blood, Wharton's jelly, amniotic fluid) have been additionally regarded as a promising tool for the treatment of those renal diseases where renal architecture has not yet been altered. The following is a non-exhaustive list of therapy approaches using these cells for kidney regeneration. The non-hematopoietic adherent cell population of BM known as Bmesenchymal stem cells^or Bmesenchymal stromal cells^(MSCs) [11, 12] was shown to improve renal function in rodent and feline CDK models [13, 14] . Potential efficacy of autologous MSCs as therapy for autosomal dominant polycystic kidney disease (ADPKD) is now being assessed in human clinical trials (https://clinicaltrials.gov/ct2/show/ NCT02166489). The regenerative potential of human amniotic fluid stem cells (AFSCs) was compared with that of BM-derived human MSCs [15] . AFSCs promoted histological and functional amelioration of renal damage comparable to that of MSCs. Moreover, both types of stem cells stimulated proliferation of tubular epithelial cells. However, the quantification of proliferating tubular cells revealed that the kinetics of proliferation induced by MSCs and AFSCs was different. MSCs promoted an early tubular proliferation, whereas proliferation induced by AFSCs was delayed and persisted up to 21 days after injury. In addition, AFSCs exerted a pronounced anti-apoptotic action on tubular cells, whereas MSCs were less effective. In kidneys with acute tubular necrosis caused by glycerol-induced rhabdomyolysis, human AFSCs had the ability to modulate the immune response and restore physiological kidney function parameters to normal levels [16] . Similarly, when injected in an animal model of Alport syndrome, AFSCs showed the propensity to lessen inflammation and fibrosis, and restore renal function [17] . Human cord blood-derived MSCs, delivered intravenously to immunodeficient mice with cisplatin-induced AKI, protected animals from renal function impairment and prolonged lifespan [18] .
More recently, the therapeutic potential of embryonic stem (ES) cells and induced pluripotent stem (iPS) cells has been investigated. While ES cells are unsuitable for kidney tissue repair or organ regeneration due to ethical problems as well as the potential risk of immune rejection, iPS cells could provide a better source of cells for clinical applied regeneration therapy.
The mammalian kidney is derived from the intermediate mesoderm (IM). The IM gives rise to both kidney progenitor populations, the metanephric mesenchyme (MM), and the ureteric bud (UB) epithelium, which form the nephrons and the collecting ducts, respectively. It seems unlikely that a single reprogramming strategy will generate all the different cell types comprising the adult kidney. Ideally, the simultaneous generation of both the two IM-derived progenitor populations essential for kidney formation would circumvent this problem, as subsequent differentiation would replenish the full spectrum of renal cells, leading to regeneration. However, in order to achieve this goal, the spatial, anatomical, and temporal origin of these progenitors needs to be fully elucidated.
The mechanisms underlying how the nascent mesoderm becomes committed to the IM and how the MM and UB lineage segregate from one another have only recently been clarified. Osr1 is one of the earliest markers for the IM (E8.5-E9.5) and also marks MM (E11.5-E15.5). By using Osr1-GFP knock-in mice, Taguchi et al. confirmed that the Osr1-GFP + population sorted from E11.5 and E15.5 kidneys contains colony-forming nephron progenitors [19] . Upon closer examination, the authors found that the expression of Integrina8 (Itga8) and the absence of platelet-derived growth factor receptor alpha (Pdgfrα) could further enrich for colonyforming cells. Colony-forming abilities of Osr1-GFP + cells were therefore examined at earlier stages. At E8.5, no overlap of GFP with Itga8 was detected and the GFP + population did not form any colonies. However, at E9.5, the GFP + population possessed the ability to form colonies. Since these cells were only detected in the anterior IM, authors hypothesized that they may represent mesonephric nephrogenic progenitors. It was also thought that the non-colony-forming cells located in the posterior IM could be a precursor population for the metanephric nephron progenitors. When this posterior section of the E9.5 embryos was plated and treated with specific growth factors, metanephric nephron progenitors were derived. Interestingly, many combinations of growth factors failed to induce metanephric nephron progenitors from OSR1 + cells at E8.5 but colonies did form in the OSR1 − fraction. This led the authors to hypothesize that the posterior immature mesoderm, which was negative for OSR1, contained prospective nephron progenitors. BRACHYURY represents a marker of the primitive streak and posterior nascent mesoderm. Using an inducible BRACHYURY Cre transgenic mouse line, authors found that at E8.5, the precursor of the UB is located anteriorly in the BRACHYURY − population and is already segregated from the MM, which is localized in BRACHYURY + posterior nascent mesoderm. These findings argue against the conventional concept that the entire kidney is derived from the anteriorly formed IM, which extends caudally. Thus, the precursor of the MM is maintained and posteriorized in the BRACHYURY + state until the E8.5 postgastrulation stage. This information was later used to derive MM from pluripotent stem cells, demonstrating the possibility of generating the kidney's complex organization by mimicking the proper temporal combinations of cell signaling that occur in vivo.
Successively, another group identified the developmental mechanism regulating the preferential induction of collecting duct versus kidney mesenchyme progenitors [20] . Using this knowledge, they generated kidney organoids that contain nephrons associated with a collecting duct network surrounded by renal interstitium and endothelial cells. The relative level of collecting duct versus nephron within individual organoids could be varied by carefully balancing anteriorposterior patterning of IM with small molecules. Altogether, this study provides a platform for the investigation of kidney development and represents the first report demonstrating induction of both kidney progenitors at the same time from human pluripotent stem cells.
Despite progress in iPS cell research towards regenerative nephrology, little evidence of the therapeutic effect of iPS cells in animal models of kidney disease has been reported to date [21] [22] [23] . We have described the current status of iPS cell research and limitation for clinical practice in a recent review [24] .
Whole-kidney tissue engineering
Although cell-based therapy shows promise in experimental animal models, it cannot be applied when renal structure has been profoundly altered, as in chronically injured kidney. In this respect, kidney regeneration is needed to rebuild a whole functional kidney de novo, eliminating the need for dialysis. To build a neo-kidney, some investigators have proposed to recapitulate early stages of organogenesis by implanting the primordial kidney, also known as the metanephros.
Metanephroi develop near the caudal end of the embryo late in the fifth week of human gestation, and at E10.5 in mice through reciprocal inductive interactions between the MM and the UB. The possibility of implanting developing metanephric tissue beneath the renal capsule of a postnatal or an adult host kidney has been studied since the early 1990s [25] . However, despite many published reports, the ability of transplanted metanephroi to incorporate into the host collecting system, increasing host renal function, has never been demonstrated for isotransplants, allotransplants, or xenotransplants [26] . However, very recently, Imberti et al. showed that metanephric kidneys, upon transplantation under the kidney capsule of rats with progressive chronic nephropathy, not only undergo successful organogenesis with development into functional nephrons, but also activate a local regenerative process within the host renal tissue. Despite these promising findings, the authors did not observe an improvement of renal functional parameters or a reduction in the degree of glomerulosclerosis and fibrosis [27] .
In most of these studies, transplantation of whole metanephroi was performed. One of the greatest challenges in tissue engineering has been the unanswered question of whether single-cell suspensions can simultaneously generate both glomeruli capable of filtering blood as well as tubules capable of reabsorbing filtered macromolecules. Recently, some progress has been made in this field. Renal organoids were grown in vitro from single-cell suspensions derived from E11.5 murine kidneys and then implanted beneath the kidney capsule of athymic rat hosts. Unilateral nephrectomy was performed to enhance the potential for growth and development of the implanted tissue. To promote endogenous vascular development, the authors developed a new technique of preconditioning the organoids in culture with vascular endothelial growth factor (VEGF) followed by injection of VEGF locally into the area of implantation as well as intravenous injections into the tail vein three times each week [28, 29] . Unfortunately, the organoids were only viable for 3-4 weeks before they began to involute. Moreover, this approach may not be feasible in the fibrotic and inflammatory milieu of a chronically injured kidney. Additionally, ethical issues are raised as the rudiment transplant tissue for clinical use would have to be obtained from human fetus.
By avoiding the ethical concerns surrounding the use of ES cells, iPS cells may represent the ideal cell source for research and applications in regenerative medicine. Ideally, decellularization of porcine or discarded human kidneys and subsequent recellularization of these matrices with patientspecific iPS-derived renal cell lineages would offer a tremendous opportunity to generate a whole and functional kidney, benefiting ESRD patients. Fabrication of acellular kidney scaffolds has been attempted, and the outcomes were satisfactory in terms of maintenance of essential extracellular matrix (ECM) components after the removal of the cellular components [30] . However, few studies have addressed the repopulation of such scaffolds with kidney-specific cells [31] [32] [33] [34] . Renal-specific cell sources are a crucial component for optimal recellularization. The fundamental question remains as to what kind of cells are needed for successful kidney reconstruction. The kidney is one of the most heterogeneous tissues in the body, comprised of at least 26 terminally differentiated cell types, all recognizable by morphology, location, and function in mice at postnatal day 10 [35] . These cell types organize into functional units called nephrons. Although a large variation in total nephron number exists among humans, numbers for individual kidneys range from approximately 200,000 to >2.5 million [36] . Each nephron consists of a vascular and a tubular component. The nephron's vascular component, the glomerulus, contains permeable vessels, which receive the blood from an afferent renal arteriole. Inside the glomerulus, plasma is filtered, and the protein-free plasma, or ultrafiltrate, is collected in the Bowman's space. Once the ultrafiltrate leaves Bowman's capsule, it passes sequentially through the proximal tubule, descending and then ascending limbs of the loop of Henle, the distal tubule, and finally the collecting duct. In the proximal convoluted tubule nearly 85 % of the filtrate is reabsorbed back into the blood. Glucose, amino acids, phosphate, potassium, urea, and other organic solutes are reabsorbed from the filtrate. The reabsorption of most of the remaining water occurs as a result of the action of the countercurrent multiplier system in the loop of Henle. Finally, in the distal convoluted tubule and in the collecting ducts, hormone-controlled reabsorption of salts and water occurs. Although urine formation involves primarily filtration and reabsorption of molecules, ions, and water as described above, an auxiliary mechanism, called tubular secretion, also occurs. The unfiltered blood leaves the glomerulus via the efferent arteriole. The efferent arteriole flows into the peritubular capillaries, and, in juxtamedullary nephrons, the vasa recta. The peritubular capillaries are found alongside nephrons and permit reabsorption and secretion between blood and the inner lumen of the nephron. Conversely, vasa recta lie parallel to the loop of Henle, and help produce concentrated urine.
The renal microvasculature therefore plays a major role in maintaining hemodynamics and renal function, and injury to the renal microvasculature is emerging as a crucial determinant of the progressive deterioration of renal function [37] . It turns out that in order to rebuild a functional and long-lasting kidney, not only do we need to select the appropriate kidney stem/progenitor cell populations and arrange these cells into the nephron's complex three-dimensional (3D) structure, but we must also provide the newly developed graft with replacement blood vessels, when using scaffolds. On the contrary, tissue vascularization and integration with the host circulation spontaneously occurs when cells are transplanted in blood vessel-enriched sites.
3D information about nephron architecture and the structural and functional relationships between the nephron tubules and their associated blood vessels has been widely investigated using different approaches which include in vitro perfusion [38] , electron microscopy [39] , and more recently, microcomputed tomography [40] . This information can be used to build a 3D functional kidney where blood flow, glomerular filtration, hormone secretion, and waste removal from the developing organ are carefully coordinated.
Simultaneous induction of progenitors for both collecting duct and nephrons via the directed differentiation of human pluripotent stem cells has been recently described [20] . Nevertheless, these cells have not been analyzed in functional, in vivo models. The possibility exists that iPS cells require 3D environments or even transplantation into live animals to fully mature [41] . Indeed, although these cells can partially differentiate along a given cell lineage in vitro, in most cases, their progeny survive very poorly in vivo, failing to completely mature and generate a source of functional cells required for tissue repair [42, 43] . As previously stated, several studies have shown that it is possible to integrate new filtering nephrons into kidneys [25, 44, 45] . This integration, if accompanied by incorporation into the host collecting system, would then represent a strategy for increasing renal function. However, to be applicable to humans with ESRD, metanephroi must incorporate into host nephrons in end-stage kidneys that are smaller with fibrotic cortex, sclerotic glomeruli, thickened arteries, and scattered chronic inflammatory cells infiltrates [46] . Thus, the challenge will be attaining greater neonephron longevity, perhaps by exploration of other potential implantation sites-rather than orthotopic sites-that might enhance nephron growth and function.
Autologous ectopic transplantation, where an autologous graft is placed back into the patient, in a non-native site, may one day revolutionize the treatment of kidney disease. Hammerman's group first suggested whole-rat metanephroi implanted into the omentum might enlarge, become vascularized, and form mature tubules and glomeruli [45] . However, other studies showed that transplanted metanephroi can grow and develop for only a short time in the host omentum [47] unless an end-to-end anastomosis to the host ureters is performed [48] . Only a few reports have shown that it is technically feasible to microsurgically connect donor and host ureters. In these studies, ureteroureterostomy slowed progression of kidney failure in nephrectomized animals [49] , prolonged short-term survival of anephric rats [48] , or raised blood pressure in acutely hypotensive rats [50] . Although promising, these results point to several clinical limitations, including postoperative adhesions and intestinal obstruction following omental manipulation [51, 52] . Transplantation sites other than the omentum might therefore be needed for successful restoration of renal function.
Generating an ectopic kidney in a lymph node
For cell or tissue transplantation to be effective, a hospitable site must be relatively accessible, provide sufficient space for cell expansion, and offer access to vasculature to support longterm engraftment [53] . In addition, because orthotopic cellbased therapy directed at a diseased organ may not be feasible, transplantation and functional growth of cells and tissue at an ectopic site can be viewed as an alternative method to provide compensatory function for the damaged native organ [53, 54] . In our search to find a transplantation site for cells and tissues, we found that the lymph nodes provide an exceptional site. There are over 500 lymph nodes in the human body, many of which are relatively easily accessible. Although a single lymph node structurally limits the number of donor cells that can be transplanted, it is technically feasible to transplant more than one lymph node to gain sufficient organ or tissue function. Importantly, the potential loss of function in a few lymph nodes does not seem to compromise the overall function of the lymphatic system [55] . In addition, transplantation and engraftment of allogeneic cells in lymph node is possible with classic immunosuppressive regimens, presenting no specific barriers at this site. Moreover, lymph nodes have ready access to the bloodstream, and can therefore foster cell growth by providing nutrients as well as hormones and growth factors. Importantly, new angiogenesis occurs fast enough to sustain cell survival and engraftment of normal tissues. We therefore hypothesized that the lymph node meets all criteria for consideration as a viable transplantation site [53] .
In our previous findings, we demonstrated the lymph node as a relevant site for transplantation of several tissues including adult liver, thymus, and pancreatic islets, thanks to its high vascularization and accessibility [56] [57] [58] [59] . More recently, we investigated whether a mouse kidney could integrate and mature in a host mouse lymph node [60] . Here, fetal renal tissues were harvested from E14-15.5 mice, minced into small pieces, and injected into lymph nodes of adult mice. As early as 3 weeks after injection, cells derived from E14-15.5 kidneys had organized into glomerular structures (Fig. 1) . Although some S-shaped bodies (glomerular and nephron precursors) could still be identified, the grafts contained several mature glomeruli, expressing CD31 + endothelial cells, and Podoplanin + podocytes. Engrafting kidneys also showed cytokeratin-8 (K8) + rudimentary tubules as well as erythropoietin adjacent to the tubules, indicating hormonal competence. We also found that kidney organogenesis within the lymph node was critically dependent on the developmental stage of the transplanted renal tissues. Indeed, while donor embryonic kidney tissues acquired more mature morphological characteristics within the lymph node, newborn kidney tissues often formed imperfect glomeruli. The most likely explanation is that the embryonic kidney donors contained more stem/ progenitor cells than the postnatal kidneys. By 6 weeks, mature nephrons consisting of mature glomeruli as well as renal tubules were observed. Moreover, erythrocyte presence inside the mature capillary tuft indicated probable glomerular filtration ability. To assess tubular maturation, we performed reverse transcription polymerase chain reaction (RT-PCR) analysis for the presence of different urea transporters (UT-A1, UT-A2, UT-A3, and UT-B) and erythropoietin. UT-A transporter immunoreactivity appears first in E16 kidneys and strongly increases after birth [61] . Interestingly, we found all UT-A family members analyzed to be expressed at the mRNA level in 6-week grafts, suggesting tubular epithelial maturation and likely de novo acquisition of ureareabsorbing ability (Fig. 2) . As expected, UT-B mRNA was detected in both control and repopulated lymph nodes as its expression in erythrocytes and other non-renal tissues is well documented [62] . Erythropoietin production was also confirmed in 6-week grafts by RT-PCR analysis of mRNA isolated from phlebotomized mice, again demonstrating endocrine function of the grafts.
By 12 weeks, five of eight 12-week ectopic grafts analyzed were comprised of fluid-filled/dilated tubules. Histological analysis indicated the thin descending limb of Henle's loop or the proximal convoluted tubule as the possible origin (for details, see [60] ). Inside these dilated tubules, urinary crystals as well as eosinophilic proteinaceous material were observed (Fig. 3) .
To determine whether the fluid represented urine trapped within the lymph nodes, we measured urea nitrogen, as urine is the only body fluid in which urea is concentrated above serum levels. Indeed, while serum urea nitrogen levels were equivalent in transplanted mice versus control mice, fluid obtained from engrafted lymph nodes showed urea concentration far above serum levels, while non-engrafted lymph fluid did not contain any urea nitrogen (Fig. 3) . This data strongly demonstrates the engrafted lymph nodes support functional kidney elements possessing glomerular filtration ability and at least partial tubular function.
To assess whether the ectopic kidney grafts could proliferate in response to growth stimuli, we performed either a left nephrectomy or a sham operation 12 days after kidney injection into the lymph node. The grafts were then collected 14 days later. Compared to grafts isolated from shamoperated mice, the engrafted lymph nodes isolated from mice that had undergone a nephrectomy were comprised of fully mature, apparently healthy nephrons or fluid-filled tubules. This outcome is comparable to our observations in 12-week grafts grown in the absence of a homeostatic signal (i.e., in a healthy recipient), where both viable and apparently functional nephrons or fluid-filled tubules were observed. In both instances, it is conceivable that as the nephron forms, it produces waste fluid, which accumulates gradually. Thus, nephrectomy accelerates ectopic kidney maturation and possibly fluid accumulation.
Next, we asked whether single-cell suspensions of embryonic kidney could organize into complex specialized components within the lymph node. Freshly isolated and dissociated E14.5 GFP + kidney cells were injected in lymph nodes, and resulting grafts were collected 6 or 12 weeks later. Not surprisingly, the number of matureappearing glomerular/nephron elements was higher in 12-week grafts than in 6-week grafts. While embryonic kidney single-cell suspension derived glomeruli tended to be less well vascularized than tissue fragment-derived glomeruli, the cell-derived grafts contained several host and/or donor-derived CD31 + vessels. for UT-A1, UT-A2, UT-A3, and UT-B urea transporters, and erythropoietin (EPO) in lymph node 6 weeks after embryonic kidney injection (6 weeks KLN) as compared to a control lymph node, RT-PCR reverse transcription polymerase chain reaction, UT urea transporters In summary, we provide a new approach for de novo whole kidney regeneration. By directly injecting the lymph node with fetal kidney tissues, we demonstrated engraftment of the donor cells and subsequent organ function.
While there is room for further improvement with regard to a contiguous collecting duct epithelium with a single path for urine, the degree of graft function observed in our study supports lymph node use to model kidney development or act as a bioreactor to grow replacement kidneys from patients' own cells. Lymph nodes adjacent to kidneys could be transplanted and graft-host ureter connection achieved through surgical and/or engineering techniques. 
